BCL2 and cancer: These findings suggest that inhibitors of NF-kB signalling, such as inhibitors of IKK, an upstream activator of NF-kB, may be used to enhance BH3-mimetic drug or chemotherapeutic drug induced killing of cancer cells by reducing the levels of pro-survival BCL-2 proteins.